Related Clinical Trials

Benefits

Comparisons

Evidence quality

Highlighted claims

• STROKE AF enrolled 492 patients with stroke attributed to LAD or SVD. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
• ARTESIA found apixaban reduced stroke or systemic embolism versus aspirin in patients with subclinical AF and CHA2DS2-VASc of at least 3, while increasing major bleeding risk. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
• CRYSTAL AF previously found ICM to be 8.8 times more effective than standard of care for detecting atrial fibrillation in cryptogenic stroke patients. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
• PER DIEM found numerically fewer recurrent strokes with ICM monitoring than with external loop recorder monitoring, but was underpowered and did not establish a significant benefit. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
• ATTICUS found no significant difference in new ischemic lesions between empirical DOAC therapy and ICM-monitored aspirin therapy switching to DOAC after AF detection, but was underpowered for recurrent stroke differences. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA